Lupin Limited

Overview

Lupin Limited is a pharmaceutical company with a Mumbai corporate base and businesses across India and international markets. Its portfolio combines generic formulations, specialty medicines, biosimilars, active pharmaceutical ingredients and selected healthcare services. These activities share scientific and regulatory foundations but operate through different technologies, customer channels and economic models. The group is therefore broader than any one tablet, inhaler or consumer brand. [1][8][9][11]

The business was founded in 1968 by Dr. Desh Bandhu Gupta, while the listed legal entity’s incorporation year is 1983. The official founder story and statutory identity disclosure answer different questions: one explains entrepreneurial origins, the other identifies the company whose securities and accounts are being discussed. This profile retains both dates and distinguishes the consolidated pharmaceutical group from the standalone listed company. [2][3]

Company identity & key facts

A person can hold a group-wide role while local subsidiaries retain their own executives and obligations. The listed company’s address is not a directory of every factory, laboratory or subsidiary. For an operational enquiry, use the relevant site or country organisation shown on the official directories. [18][14]

History & selected milestones

1. 1968Dr. Desh Bandhu Gupta founds Lupin; the company’s history records a small initial team and borrowed seed capital.
2. Early businessAn order for iron and folic acid tablets for an Indian government programme becomes an important initial assignment.
3. 1983The current listed legal entity’s incorporation year.
4. 2008Lupin Biotech is established in Pune for biosimilar research and manufacturing.
5. 2017The LupinLife consumer-health business begins, according to the adjacencies directory.
6. 2021Lupin Diagnostics is launched.
7. 2026The company’s history records a further Atharv Ability rehabilitation-centre opening in Delhi.
8. 6 August 2026The board records Q1 FY2026–27 financial results for the quarter ended 30 June.

These milestones describe selected changes in the business. The original records provide the fuller chronology. [2][3][10][11][6]

How the business makes money

Lupin develops, manufactures, sources and commercialises pharmaceutical products through multiple market channels. Generic medicines and APIs serve different customers from specialty brands and diagnostic services. Generic formulations can be sold through wholesalers and pharmacy systems, while ingredients are supplied to manufacturers. Specialty businesses may involve licensing, territory rights and focused commercial teams alongside scientific development. [8][9][13]

Analytical context: a pharmaceutical product moves through development, validation, submission, approval and launch before it can generate sustainable commercial value. Each stage carries costs and uncertainty. Product price, volume, competition, supply reliability and market access influence sales after approval. Scientific capability therefore has to work with manufacturing, quality, procurement and distribution rather than being assessed solely by the number of products in a research pipeline. [12][13]

Major business activities

Global generics form a substantial part of the business, with formulations sold across developed and emerging markets. The Indian business combines branded products with commercial capabilities adapted to local practice. APIs and process chemistry are another industrial component. Geography, product category and legal entity are different reporting views, so a country business can contain several technologies and more than one operating company. [8][18]

Specialty and innovation include respiratory products in the United States and selected neurology, ophthalmology and other portfolios internationally. The specialty page identifies Xopenex HFA, NaMuscla and country-specific brands as examples. These names help map the commercial portfolio without making a clinical recommendation or assuming identical rights and availability worldwide. [9]

Biosimilars require biological development and manufacturing capabilities distinct from conventional chemical synthesis. Lupin’s dedicated Pune biotechnology centre is described as covering development through clinical and commercial supply. The adjacencies portfolio adds consumer health, diagnostics, digital health and rehabilitation. These are distinct healthcare business models, not additional pharmaceutical sales categories that can automatically be added to the financial total. [10][11]

Brands, products & operating identities

A brand may be acquired, licensed or commercialised only in selected territories. A country subsidiary’s name also does not identify every product it sells. Current product documents and transaction terms are needed for a precise ownership, approval or availability claim. [9][5]

Group structure & accounting perimeter

Lupin’s standalone accounts report the Indian listed legal company, while consolidated statements incorporate the relevant group entities under accounting rules. Its FY2025–26 business responsibility report explicitly uses a standalone boundary. A headcount, plant total or export percentage from that report must therefore retain that qualifier rather than being turned into an all-group global measure. [3][5]

The global-presence directory connects readers with operating businesses such as Hormosan, Laboratorios Grin and MedQuímica. These have local functions within the wider group. A commercial partner or licensed brand can also be important without being a controlled subsidiary, making the annual subsidiary and investment notes essential for precise legal relationships. [18][5]

Analytical context: acquisitions can change the balance sheet through goodwill and other intangible assets as well as broaden sales. A transaction announcement, completion date and start of financial consolidation are related but separate milestones. Comparing results through portfolio changes requires a consistent scope and attention to exceptional costs, amortisation and any disposed businesses. [5][9]

Leadership, ownership & governance

The reviewed leadership directory identifies Manju D. Gupta as Non-Executive Chairperson, Vinita Gupta as CEO and Nilesh D. Gupta as Managing Director. Ramesh Swaminathan is Executive Director, Global CFO, and Head of IT and API Plus SBU. The distinction between chairperson, CEO, MD and finance leadership helps explain responsibilities without treating family history as a complete management chart. [4]

The same directory identifies separate leaders for technical operations, research, quality, biotechnology, geographies and manufacturing solutions. A global pharmaceutical business needs these specialised responsibilities as well as board oversight. The governance page and annual report provide the formal policy and committee framework; the shareholding archive identifies promoter and public holdings at particular quarter-ends. [4][16][17]

Analytical context: ownership concentration, related-party transactions and capital allocation are standard governance subjects for a listed company. An undated family ownership estimate is less useful than the legal categories and effective date in a current shareholding disclosure. [17]

Offices, manufacturing & research locations

The registered and corporate office is Kalpataru Inspire in Santacruz East, Mumbai. The manufacturing directory lists Indian locations including Aurangabad, Ankleshwar, Mandideep, Vadodara, Visakhapatnam, Nagpur, Pithampur, Tarapur, Pune, Jammu, Goa and Sikkim, with functions varying by site. It also lists Somerset in the United States, Laboratorios Grin in Mexico and MedQuímica in Brazil. This is a guide to selected locations, not a claim that every site makes every product. [3][14]

Pune has a dedicated biotechnology role, while the directory identifies API, formulation, ophthalmic, inhalation and other specialisations elsewhere. The technical-operations model links manufacturing with procurement and supply-chain planning. Analytical context: specialised facilities allow different processes and quality controls, but also require reliable coordination of materials, authorisations and finished-product supply. [10][13][14]

Sales reach and manufacturing footprint are not interchangeable. A country can be served by imported product, a distributor or a local subsidiary without containing a group-owned factory. The country websites and global-presence directory provide more appropriate contacts for local enquiries. [18]

Dated financial performance

The release distinguishes sales from revenue from operations and states that EBITDA includes foreign-exchange and other income. It also deducts non-controlling interests after the headline PAT. Those definitions matter when comparing Lupin with an issuer using a different operating-profit or shareholder-profit measure. One crore equals ten million rupees. [6]

This is a dated June-quarter snapshot, not an assertion that no subsequent results exist. The quarterly archive reviewed for this profile displayed the Q1 set for FY2026–27. Use that archive and exchange filings for later statements. Annual results, standalone sustainability figures and consolidated quarterly accounts have different periods and scopes. [7][3]

Analytical context: cash generation, working capital, taxes, development investment and acquisition spending should be considered alongside profit. A strong quarterly margin is not automatically a sustainable full-year run rate. [5]

Research, specialty & technology direction

The scientific portfolio includes conventional generics, complex dosage forms and biosimilars. The research page describes capabilities and development platforms, while the biotechnology page explains a model spanning cell-line and process development, analytical characterisation and regulated manufacturing. These capabilities support product development but do not guarantee that a candidate will be approved, launched or commercially successful. [12][10]

The specialty directory illustrates a geographical approach to selected products, and adjacencies extend the group into diagnostics, consumer health, digital care and rehabilitation. Analytical context: each expansion brings a different operating model, skill requirement and customer-acquisition process. A diagnostics collection network, a prescription brand and a digital platform should therefore be evaluated using measures appropriate to the activity rather than a single undifferentiated product count. [9][11]

People, skills & operational culture

Lupin’s technical-operations material describes integration of manufacturing, procurement and supply-chain work. It also discusses training and capability building, including inspection-readiness practices and factory-level learning. The careers portal provides current opportunities, while leadership and function pages explain the range of scientific, commercial and technical roles across the group. [13][21][4]

Analytical context: pharmaceutical reliability requires people to investigate deviations, maintain accurate records, validate processes and escalate safety concerns. A digital tool can support those tasks without replacing professional judgement or accountability. Workforce measures also need scope: employees and workers, permanent and other-than-permanent categories, and standalone versus consolidated coverage can all produce different totals. Retaining those definitions makes workforce reporting more useful than publishing an undated global headcount. [3][15]

Sustainability & community development

The sustainability pages describe environmental, social and governance priorities, while the FY2025–26 statutory report provides a defined standalone reporting boundary. Energy, water, waste, occupational safety and governance are relevant to pharmaceutical manufacturing. An improvement in one site or category should not be presented as a complete global result without matching the report’s scope and year. [19][3]

Community activity follows the founder’s emphasis on social development, with the Lupin Human Welfare and Research Foundation associated with rural and community programmes. Analytical context: healthcare access, livelihoods and rural development involve partnerships and long implementation periods. Spending, participation and measured outcomes should remain separate. Targets express intended future performance; assurance documents explain which reported indicators were independently assessed and at what level. [2][20][19]

Recent developments & update trail

The company’s 2026 materials show a portfolio extending beyond conventional generics: specialty brands, biosimilars, diagnostics, digital health and rehabilitation sit alongside the established pharmaceutical business. The founder-history page records an Atharv Ability opening in Delhi during 2026. These developments should be followed through the corresponding operating and financial disclosures rather than assumed to contribute equally to group sales. [2][11][9]

The 6 August 2026 release provides the historical quarterly snapshot used in this profile. A later approval, partnership or acquisition announcement can change the forward business context without rewriting that earlier quarter. The annual and quarterly archives provide the route to subsequent updates, and any new figure should retain its date, currency unit, reporting perimeter and definition. [6][7][5]

Business risks & regulatory context

Analytical context: the business faces generic competition, pricing pressure, product-development uncertainty, regulatory requirements, intellectual-property issues and supply-chain dependencies. Specialty and biosimilar programmes can involve lengthy development and market-access work. International operations add currency and local-market exposure. Acquisition integration, goodwill and development spending create further capital-allocation questions that should be assessed through the accounts. [5][12][9]

Quality policy is not the same thing as a facility’s latest inspection classification. A regulatory update should specify the site, agency, date, observation or decision and subsequent status. This profile does not infer unresolved violations or universal clearance from the corporate quality page. It explains the business and its sources; individual medicine use belongs to the relevant product information and qualified healthcare advice. [15]

Frequently asked questions

A plain-language business glossary

Generic formulation

A finished medicine developed under the applicable requirements for an established reference product.

Biosimilar

A biological medicine assessed for high similarity to an approved reference biologic.

API

Active pharmaceutical ingredient used in finished medicines.

Specialty portfolio

Products and commercial capabilities organised around selected, often specialised therapeutic markets.

Non-controlling interest

The part of a subsidiary’s equity or profit attributable to owners outside the parent group.

IND-AS

Indian Accounting Standards, the stated framework for the financial snapshot.

Pharmacovigilance

Monitoring, assessment and reporting of medicine-safety information.

Standalone BRSR

Business responsibility and sustainability reporting for the specified listed legal company boundary.

Reports & research documents

Use financial statements for accounting figures, annual reports for the wider business and governance picture, and dated announcements for subsequent developments. Figures with different reporting boundaries or periods should be compared only after checking their definitions.

Sources, review date & editorial scope

Reviewed: 3 November 2026. This profile combines original explanations with the linked official company publications and regulatory filings. Financial tables retain their currency, period and reporting basis. Company targets, forecasts and product claims are attributed to their issuer.

Products, entities, locations and developments are selected for orientation. The linked disclosures contain fuller subsidiary registers, accounting notes, governance reports and risk information. A later filing may change a fact recorded here. Historical announcements are dated so they are not mistaken for current appointments or completed transactions.

1. Company overview ↗Lupin Limited · reviewed 3 Nov 2026
2. The Lupin story and founder ↗Lupin Limited · reviewed 3 Nov 2026
3. FY2025–26 business responsibility and sustainability report ↗Lupin Limited · reviewed 3 Nov 2026
4. Board and executive leadership ↗Lupin Limited · reviewed 3 Nov 2026
5. Integrated report FY2025–26 ↗Lupin Limited · reviewed 3 Nov 2026
6. Q1 FY2026–27 results, 6 August 2026 ↗Lupin Limited · reviewed 3 Nov 2026
7. Quarterly statutory results and presentations ↗Lupin Limited · reviewed 3 Nov 2026
8. Global generics business ↗Lupin Limited · reviewed 3 Nov 2026
9. Specialty and innovation businesses ↗Lupin Limited · reviewed 3 Nov 2026
10. Biosimilars development and manufacturing ↗Lupin Limited · reviewed 3 Nov 2026
11. Consumer health, diagnostics, digital health and rehabilitation ↗Lupin Limited · reviewed 3 Nov 2026
12. Research and scientific capabilities ↗Lupin Limited · reviewed 3 Nov 2026
13. Global technical operations ↗Lupin Limited · reviewed 3 Nov 2026
14. Manufacturing sites and functions ↗Lupin Limited · reviewed 3 Nov 2026
15. Quality in action ↗Lupin Limited · reviewed 3 Nov 2026
16. Compliance, ethics and governance ↗Lupin Limited · reviewed 3 Nov 2026
17. Quarterly shareholding patterns ↗Lupin Limited · reviewed 3 Nov 2026
18. Global presence and operating companies ↗Lupin Limited · reviewed 3 Nov 2026
19. Sustainability and ESG approach ↗Lupin Limited · reviewed 3 Nov 2026
20. Community and rural-development programmes ↗Lupin Limited · reviewed 3 Nov 2026
21. Official careers portal ↗Lupin Limited · reviewed 3 Nov 2026